TSLP protein: an epithelial cell-derived alarmin and the core initiator of the allergic inflammatory cascade

Author: Senior Product Manager of UA Views：9

TSLP protein

Recent Advances
Product Information

Recent Advances

TSLP Protein: An Epithelial Cell-Derived Alarmin and the Core Initiator of the Allergic Inflammatory Cascade

Summary: This article focuses on the molecular characteristics and immunoregulatory functions of thymic stromal lymphopoietin (TSLP), systematically elaborating the molecular mechanism by which this IL-7-like epithelial cell-derived cytokine activates the JAK2-STAT signaling pathway through the TSLPR/IL-7Rα ternary receptor complex, analyzing the core initiating role of TSLP in type 2 inflammatory diseases such as allergic rhinitis, asthma, atopic dermatitis, and food allergy, and exploring its clinical value as a therapeutic target for allergic asthma.

I. The Immunological Basis of Allergic Diseases and the Central Role of Epithelial Cells.

The most common forms of allergic diseases are allergic rhinitis, asthma, atopic dermatitis, and food allergy. The immune cells involved in the initiation and progression of allergic inflammation mainly include dendritic cells, mast cells, basophils, eosinophils, and type 2 helper T cells. The interaction between epithelial cells and immune cells is crucial in both innate and adaptive immune responses. In addition to providing a barrier for the body, epithelial cells also express a variety of cell surface and secreted factors to appropriately control immune responses. Although various epithelial cell-derived cytokines can influence immune responses, the most thoroughly studied in the context of allergic inflammation is thymic stromal lymphopoietin. The formation of this research landscape stems from the upstream initiating position of TSLP in the allergic inflammatory cascade——it is not only one of the first signal molecules released by epithelial cells after sensing external stimuli, but also a key bridge connecting the epithelial barrier with downstream immune cell activation.

II. Molecular Characteristics and Cellular Sources of TSLP.

TSLP is an interleukin-7-like epithelial cell-derived cytokine associated with human allergic diseases. It plays an important role in the maturation of T cell populations by activating antigen-presenting cells. TSLP is mainly produced by non-hematopoietic cells, such as fibroblasts, epithelial cells, and various types of stromal or stromal-like cells. Under normal physiological conditions, TSLP is mainly expressed by epithelial cells in the skin, intestine, and lungs; however, under inflammatory conditions, several other cells such as bronchial smooth muscle cells and lung fibroblasts also express TSLP, and high TSLP expression has been found in lesional skin of patients with atopic dermatitis. This expansion of expression from epithelial cells to stromal cells reflects the profound impact of the inflammatory microenvironment on the regulation of TSLP expression and also suggests the functional amplification effect of TSLP in chronic persistent inflammatory states.

III. The TSLP Receptor Complex and Signal Transduction Mechanisms.

TSLP forms a ternary signaling complex with the thymic stromal lymphopoietin receptor CRLF2 (TSLPR) and the IL-7Rα chain, and then activates intracellular signaling through the STATs and JAK2 pathways. The assembly mode of this ternary receptor complex enables TSLP to utilize the shared subunit IL-7Rα for signal cross-regulation with other members of the IL-7 family, and also determines the tissue specificity of TSLP signaling. The expression distribution of TSLPR limits the target cell range of TSLP, while the broad expression of IL-7Rα confers on TSLP the potential to exert regulatory functions in a variety of immune and non-immune cells. Activation of the JAK2-STAT pathway ultimately leads to transcriptional reprogramming of target genes, driving dendritic cell activation and the initiation of type 2 immune responses.

IV. Molecular Mechanisms by Which TSLP Initiates the Allergic Inflammatory Cascade.

Allergen or viral challenge triggers mucosal epithelial cells or skin cells to produce TSLP. TSLP binds to its receptor and activates immature dendritic cells; TSLP-activated dendritic cells produce the chemokines IL-8 and eotaxin-2, which recruit neutrophils and eosinophils, as well as TARC and MDC, which recruit Th2 cells. A variety of stimuli from cells, microorganisms, or the environment can regulate TSLP expression, many of which are related to allergic inflammation. This mechanistic chain clearly depicts the functional positioning of TSLP as the initiator of the inflammatory cascade: epithelial cells sense allergen or viral stimuli and release TSLP; TSLP acts on dendritic cells to activate them; activated dendritic cells recruit neutrophils, eosinophils, and Th2 cells to the inflammatory site by secreting multiple chemokines, ultimately forming a type 2 inflammatory microenvironment characterized by Th2 cell and eosinophil infiltration.

V. Clinical Value of TSLP as a Therapeutic Target for Allergic Asthma.

As a central regulator of allergic asthma, TSLP has become one of the most sought-after targets for asthma treatment, and TSLP is one of the initiators of the inflammatory cascade, closely related to the occurrence of allergic diseases such as atopic dermatitis, asthma, and chronic sinusitis. The upstream position of TSLP in the inflammatory cascade makes it an ideal intervention node for blocking type 2 inflammation——compared with targeting downstream cytokines (such as IL-4, IL-5, and IL-13), blocking TSLP may simultaneously inhibit the activation of multiple downstream pathways, thereby producing a broader anti-inflammatory effect. Monoclonal antibodies against TSLP have entered clinical development for the treatment of severe asthma and atopic dermatitis, and preliminary results have validated the clinical feasibility of targeting TSLP. In addition, TSLP also plays an important role in upper airway type 2 inflammation such as chronic sinusitis with nasal polyps, further expanding the range of indications for its use as a therapeutic target.

VI. Conclusion.

In basic research and drug development related to TSLP, high-quality recombinant TSLP protein is a core tool for dissecting the binding mechanism between TSLP and the TSLPR/IL-7Rα receptor complex and for evaluating the activity of targeted drugs. The R127A and R130A double mutant form alters the interaction interface between TSLP and its receptor through site-directed mutagenesis and can be used to study the key amino acid residues involved in TSLP receptor binding and their effects on signal activation. The His tag facilitates purification by immobilized metal affinity chromatography and enables detection and capture by anti-His tag antibodies. To meet the needs of TSLP functional research and exploration of allergic inflammation mechanisms, UA provides TSLP (R127A, R130A) His Tag Protein, Human. This product is suitable for applications such as binding activity analysis of TSLP with the TSLPR/IL-7Rα receptor complex, research on the effects of TSLP mutants on JAK2-STAT signaling pathway activation, in vitro screening and evaluation of TSLP-targeting antibodies, and mechanistic research related to allergic asthma and atopic dermatitis.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next